Rare blood diseases Archives

Investors Hand Disc Medicine $90 Million to Control Hematological Diseases

Biopharma, Business, Erythropoietic Protoporphyria (EPP), Financing, Hematologic Diseases, Investors, Metabolism, Myelofibrosis, R&D, Rare blood diseases, Red Blood Cells, Series B

Investors Hand Disc Medicine $90 Million to Control Hematological Diseases Published: Sept. 2, 2021 By Heather McKenzie BioSpace A two-year-old biopharma company tackling rare blood diseases has received a […]

FDA Approves First Drug to Treat Group of Rare Blood Disorders in Nearly 14 Years

Approvals, Eosinophils, FDA, FDA/Regulatory, Hypereosinophilic Syndrome (HES), Organ Damage, Rare blood diseases, White Blood Cells

The U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.

Apellis’ PNH Drug Beats Alexion’s Soliris in Phase III

Blockbusters, Blood Diseases, Clinical Trial Endpoints, Clinical Trials, Hemoglobin levels, Paroxysmal Nocturnal Hemoglobinuria (PNH), R&D, Rare blood diseases, Red Blood Cells, Stocks, Superiority

Apellis Pharmaceuticals’ pegcetacoplan beat out Alexion Pharmaceuticals’ Soliris in the Phase III PEGASUS study in adults with paroxysmal nocturnal hemoglobinuria (PNH).